Ticker	Volume	Price	Price Delta
DJIA	12,454.80	-74.92	-0.60%
S&P 500	1,317.82	-2.86	-0.22%
Nasdaq	2,837.53	-1.85	-0.07%

Ticker	Volume	Price	Price Delta
STOXX 50	2,161.87	+5.35	0.25%
FTSE 100	5,351.53	+1.48	0.03%
DAX	6,339.94	+24.05	0.38%

Ticker	Volume	Price	Price Delta
Nikkei	8,580.39	+17.01	0.20%
TOPIX	722.11	-0.14	-0.02%
Hang Seng	18,713.40	+47.01	0.25%

Gold

1,571.20

+0.73%

EUR-USD

1.2579

0.4946%

Nasdaq

2,837.53

-0.07%

DJIA

12,454.80

-0.60%

S&P 500

1,317.82

-0.22%

FTSE 100

5,351.53

+0.03%

STOXX 50

2,161.87

+0.25%

DAX

6,339.94

+0.38%

Oil (WTI)

90.86

+0.22%

U.S. 10-year

1.738%

-0.039

BAC:US

7.15

+0.14%

FB:US

31.91

-3.39%

Bloomberg

Exchange: -
Sector: Consumer, Non-cyclical
Industry: Biotechnology
Sub-Industry: Medical-Biomedical/Gene

Anadys Pharmaceuticals Inc

ANDS:US

Acquired

As of 11/23/2011.

Anadys Pharmaceuticals Inc (ANDS:US) was acquired by ROG:VX

Company Profile

Anadys Pharmaceuticals Inc. provides biopharmaceuticals. The Company discovers, develops, and commercializes small molecule, anti-infective medicines for the treatment of hepatitis C virus, or HCV, and bacterial infections. Anadys has several programs underway to deliver other HCV drug candidates.